TY  -  
T1  - The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes 
SN  -  /  
UR  - http://hdl.handle.net/10138/224129 
T3  -  
A1  - Cherney, David; Lund, Soren S.; Perkins, Bruce A.; Groop, Per-Henrik; Cooper, Mark E.; Kaspers, Stefan; Pfarr, Egon; Woerle, Hans J.; von Eynatten, Maximilian 
A2  -  
PB  -  
Y1  - 2016 
LA  - eng 
AB  - Aims/hypothesis Sodium glucose cotransporter 2 (SGLT2) inhibition lowers HbA(1c), systolic BP (SBP) and weight in patients with type 2 diabetes and reduces renal hyperfiltration associated with type 1 diabetes, suggesting decreased intraglomerular hypertension. As lowering HbA(1c), SBP, weight and intraglomerular pressure is associated with antialbuminuric effects in diabetes, we hypothesised that SGLT2 inhibition would reduce the urine albumin-to-creatinine ratio (UACR) to a clinically meaningf... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - Empagliflozin; Macroalbuminuria; Microalbuminuria; Sodium glucose cotransporter 2; Type 2 diabetes; Urine albumin-to-creatinine ratio; PLACEBO-CONTROLLED TRIAL; CHRONIC KIDNEY-DISEASE; DOUBLE-BLIND; SGLT2 INHIBITOR; LONG-TERM; ADD-ON; DIETARY-SODIUM; ALBUMINURIA; RATS; HYPERFILTRATION; 3121 General medicine, internal medicine and other clinical medicine 
N1  -   
PP  -  
ER  -